Abstract
The recent successful clinical translation of nuclear theranostics ([1][1],[2][2]) fueled industry investment in the radiopharmaceutical market ([3][3]). Among other examples, Novartis invested $6 billion to acquire Endocyte (177Lu-PSMA-617) and Advanced Accelerator Applications (AAA; 177Lu-DOTATATE
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Paper Title
Journal
Date
